Sitavia: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Sitagliptin

Indications/Uses

Adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM as monotherapy, or in combination w/ metformin, sulfonylurea, or PPARγ agonist (ie, thiazolidinedione) as initial therapy, or combination w/ metformin & sulfonylurea, or metformin & PPARγ agonist (ie, thiazolidinedione), when single agent alone or dual therapy, w/ diet & exercise, does not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in combination w/ insulin (w/ or w/o metformin).

Click to view Sitavia detailed prescribing information

Dosage/Direction for Use

100 mg once daily as monotherapy or combination therapy w/ metformin, sulfonylurea, insulin (w/ or w/o metformin), PPARγ agonist (eg, thiazolidinediones), metformin + sulfonylurea, or metformin + PPARγ agonist. Renal impairment w/ estimated GFR (eGFR) ≥30 to <45 mL/min/1.73 m² 50 mg once daily, ≥15 to <30 mL/min/1.73 m² or ESRD w/ eGFR <15 mL/min/1.73 m² requiring hemodialysis or peritoneal dialysis 25 mg once daily, may be administered w/o regard to timing of dialysis.

Click to view Sitavia detailed prescribing information

Overdosage

View Sitavia overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

Click to view Sitavia detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Sitavia detailed prescribing information

Special Precautions

Not to be used in patient w/ known hypersensitivity; type I diabetes, diabetic ketoacidosis; severe infection or serious accident. Severe disabling arthralgia. May increase risk of severe joint pain. Closely monitor patients for signs & symptoms pancreatitis after bariatric surgery. Not to be used concomitantly w/ alcohol. Moderate & severe renal impairment. Not recommended during pregnancy. Lactation.

Click to view Sitavia detailed prescribing information

Use In Pregnancy & Lactation

Click to view Sitavia detailed prescribing information

Adverse Reactions

Nasopharyngitis, URTI, peripheral edema, headache, hypoglycemia.

Click to view Sitavia detailed prescribing information

Drug Interactions

Increased absorption & renal clearance w/ P-gp inhibitors. Potential additive effect on active glucagon-like peptide (GLP-1) conc w/ metformin. Concomitant use w/ digoxin.

Click to view Sitavia detailed prescribing information

Storage

View Sitavia storage conditions for details to ensure optimal shelf-life.

Description

View Sitavia description for details of the chemical structure and excipients (inactive components).

Action

View Sitavia mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Thai FDA Category

Presentation/Packing

Form

Sitavia FC tab 100 mg

Packing/Price

3 × 10's

Form

Sitavia FC tab 50 mg

Packing/Price

3 × 10's

Sitavia

sitagliptin

Manufacturer:

MacroPhar

Distributor:

MacroPhar Lab